AprilBio Co Ltd
KOSDAQ:397030
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11 070
25 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AprilBio Co Ltd
Total Liabilities & Equity
AprilBio Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
Total Liabilities & Equity
₩79.7B
|
CAGR 3-Years
60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Liabilities & Equity
₩19.9T
|
CAGR 3-Years
56%
|
CAGR 5-Years
40%
|
CAGR 10-Years
24%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Liabilities & Equity
₩1.9T
|
CAGR 3-Years
49%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Liabilities & Equity
₩943B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Liabilities & Equity
₩601.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Liabilities & Equity
₩299.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
AprilBio Co Ltd
Glance View
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
See Also
What is AprilBio Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
79.7B
KRW
Based on the financial report for Dec 31, 2023, AprilBio Co Ltd's Total Liabilities & Equity amounts to 79.7B KRW.
What is AprilBio Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
60%
Over the last year, the Total Liabilities & Equity growth was 12%. The average annual Total Liabilities & Equity growth rates for AprilBio Co Ltd have been 60% over the past three years .
You don't have any saved screeners yet
